Dopheide Jörn F, Sebastian Tim, Engelberger Rolf P, Haine Axel, Kucher Nils
1 Clinic for Angiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
2 Division of Angiology, Cantonal Hospital Fribourg, Fribourg, Switzerland.
Vasa. 2018 Jan;47(1):56-62. doi: 10.1024/0301-1526/a000666. Epub 2017 Oct 5.
Rheolytic thrombectomy (RT) for acute iliofemoral deep vein thrombosis (DVT) with first-generation techniques is often incomplete and adjunctive conventional catheter-directed thrombolysis (CDT) is required in more than half of patients to achieve venous patency.
From the prospective Bern Venous Stent Registry, we investigated rates of primary treatment success, primary patency, and post-thrombotic syndrome (PTS) from 40 consecutive patients (mean age 51 ± 19 years, 45 % women) with acute iliofemoral DVT, treated with a novel directional RT technology and stent placement. Overall, 24 patients were treated for native-vessel iliofemoral DVT (11 with single-session RT, 13 with bail-out RT after failed CDT) and 16 for iliofemoral stent thrombosis. Pulse-spray thrombolysis (r-tPA 10 mg) was performed in 29 (73 %) patients. The mean follow-up duration was 193 ± 132 days (minimum 90 days).
Overall, primary treatment success of RT was 95 %; only two patients required adjunctive CDT to restore patency. In 24 patients with native-vessel DVT, six-month primary patency was 92 % (95 %CI 75-99 %), and 23 patients (96 %) were free from the PTS according to the Villalta score. In 16 patients with stent thrombosis, six-month primary patency was 63 % (95 %CI 35-85 %) and 50 % were free from PTS. Except for transient macroscopic haemoglobinuria in all patients, no other side effects were recorded.
In patients with iliofemoral DVT of native or stented vessels, RT followed by stent placement appears to be effective and safe. The novel technique enables single-session DVT treatment in the majority of patients without the need for prolonged CDT.
采用第一代技术对急性髂股深静脉血栓形成(DVT)进行溶栓性血栓切除术(RT)往往并不彻底,超过半数的患者需要辅助性常规导管直接溶栓术(CDT)来实现静脉通畅。
我们从前瞻性的伯尔尼静脉支架注册研究中,调查了40例连续的急性髂股DVT患者(平均年龄51±19岁,45%为女性)采用新型定向RT技术及支架置入术后的初次治疗成功率、初次通畅率和血栓形成后综合征(PTS)发生率。总体而言,24例患者接受了原发血管髂股DVT治疗(11例接受单次RT,13例在CDT失败后接受补救性RT),16例接受了髂股支架血栓形成治疗。29例(73%)患者进行了脉冲喷射溶栓(重组组织型纤溶酶原激活剂10 mg)。平均随访时间为193±132天(最短90天)。
总体而言,RT的初次治疗成功率为95%;仅2例患者需要辅助性CDT来恢复通畅。在24例原发血管DVT患者中,6个月时的初次通畅率为92%(95%CI 75 - 99%),根据维拉塔评分,23例患者(96%)无PTS。在16例支架血栓形成患者中,6个月时的初次通畅率为63%(95%CI 35 - 85%),50%无PTS。除所有患者均出现短暂肉眼血尿外,未记录到其他副作用。
对于原发血管或支架血管的髂股DVT患者,RT后行支架置入似乎有效且安全。这项新技术能够在大多数患者中进行单次DVT治疗,而无需长时间的CDT。